ENAapplication/xmlftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/057/SRR10036557/SRR10036557_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/049/SRR10036549/SRR10036549_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/042/SRR10036542/SRR10036542_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/061/SRR10036561/SRR10036561_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/050/SRR10036550/SRR10036550_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/063/SRR10036563/SRR10036563_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/041/SRR10036541/SRR10036541_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/051/SRR10036551/SRR10036551_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/054/SRR10036554/SRR10036554_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/053/SRR10036553/SRR10036553_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/062/SRR10036562/SRR10036562_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/048/SRR10036548/SRR10036548_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/054/SRR10036554/SRR10036554_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/060/SRR10036560/SRR10036560_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/061/SRR10036561/SRR10036561_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/058/SRR10036558/SRR10036558_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/049/SRR10036549/SRR10036549_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/052/SRR10036552/SRR10036552_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/055/SRR10036555/SRR10036555_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/043/SRR10036543/SRR10036543_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/042/SRR10036542/SRR10036542_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/046/SRR10036546/SRR10036546_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/045/SRR10036545/SRR10036545_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/040/SRR10036540/SRR10036540_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/063/SRR10036563/SRR10036563_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/055/SRR10036555/SRR10036555_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/047/SRR10036547/SRR10036547_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/051/SRR10036551/SRR10036551_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/044/SRR10036544/SRR10036544_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/043/SRR10036543/SRR10036543_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/057/SRR10036557/SRR10036557_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/045/SRR10036545/SRR10036545_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/048/SRR10036548/SRR10036548_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/050/SRR10036550/SRR10036550_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/060/SRR10036560/SRR10036560_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/059/SRR10036559/SRR10036559_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/056/SRR10036556/SRR10036556_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/058/SRR10036558/SRR10036558_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/044/SRR10036544/SRR10036544_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/052/SRR10036552/SRR10036552_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/053/SRR10036553/SRR10036553_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/047/SRR10036547/SRR10036547_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/046/SRR10036546/SRR10036546_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/041/SRR10036541/SRR10036541_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/040/SRR10036540/SRR10036540_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/059/SRR10036559/SRR10036559_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/056/SRR10036556/SRR10036556_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR100/062/SRR10036562/SRR10036562_2.fastq.gzprimaryOK200GenomicsMoffitt Cancer Centerhttps://www.ebi.ac.uk/ena/browser/view/PRJNA562907Mus musculusMyeloid derived suppressor cells (MDSCs) were sorted from B16 tumor-bearing mice, WT and IL-6KO, that were untreated or given lymphodepleting cyclophosphamide and fludarbine. We report that monocytic and polymorphonuclear MDSC subsets (M-MDSCs and PMN-MDSCs respectively) have a unique gene expression profile in comparison to MDSCs collected from untreated tumor-bearing animals. Overall design: M-MDSCs and PMN-MDSCs were sorted from WT untreated mice (n=3) and lymphodepleted (LD) mice (n=3) IL-6KO untreated mice (n=3) and lymphodepleted (LD) mice. Lymphodepleting treatment was initated in mice with established tumors and MDSCs were collected from the spleens of mice 7 days after treatment.ENADifferentiation-Inducing Protein, 3.4.22.-, Myeloid Differentiation-Inducing Protein, B-Cell Stimulatory Factor-2, CDF, RNA Sequence Determination, Laboratory, Myeloid, Sequence Determination, chemotherapy, Il-6, RNA Sequence, Mus domesticus, B-cell hybridoma growth factor, Hepatocyte-Stimulating Factor, B-Cell, mini-ICE, CASP-14, pharmacotherapy, B-Cell Differentiation Factor, broad, Pharmacotherapies, House Mouse, Chemotherapies, B-cell stimulatory factor 2, B Cell, B Cell Stimulatory Factor 2, HGF, House, IL-6, Hepatocyte Stimulating Factor, Interferon beta-2, Mus musculus domesticus, Hybridoma growth factor, Growth Factor, Analysis, CTL differentiation factor, Mice, Drug Therapies, Differentiation Factor, Genomes, Analyses, Determination, Swiss, Hybridoma Growth Factor, Interleukin 6, Swiss Mice, B Cell., Sequence Determinations, Sequencing, B Cell Differentiation Factor 2, interleukin-6 receptor ligand, RNA Sequence Analyses, Therapies, RNA Sequencing, IL6, Sequence Analyses, Therapy, RNA, wide/broad, MGI-2, RNA Sequence Determinations, CASP14, mouse, B Cell Stimulatory Factor-2, beta-2, Myeloid Differentiation Inducing Protein, HSF, Cell, Determinations, BSF2, Interferon beta 2, Mus, IFN-beta-2, Mini-ICE, Chemotherapy, BSF-2, Differentiation Factor-2, B-Cell Differentiation Factor-2, Mus musculus, IFN-beta 2, Differentiation Factor 2, Pharmacotherapy, Caspase-14 subunit p10, distinct, mice, Swiss Mouse, Interleukin HP-1, House Mice, Caspase-14 subunit p19, whole genome, MICE, Plasmacytoma, Laboratory Mice, domesticus, Drug, wide, IFNB2, B Cell Differentiation Factor, Hybridoma, Plasmacytoma Growth Factor, RNA Sequence Analysis, B-Cell Stimulatory Factor 2, Mouse, pharmacologic therapy, Interferon, Laboratory MouseDifferentiation-Inducing Protein, 3.4.22.-, Myeloid Differentiation-Inducing Protein, B-Cell Stimulatory Factor-2, CDF, RNA Sequence Determination, Laboratory, Myeloid, Sequence Determination, chemotherapy, Il-6, RNA Sequence, Mus domesticus, B-cell hybridoma growth factor, Hepatocyte-Stimulating Factor, B-Cell, mini-ICE, CASP-14, pharmacotherapy, B-Cell Differentiation Factor, broad, Pharmacotherapies, House Mouse, Chemotherapies, B-cell stimulatory factor 2, B Cell, B Cell Stimulatory Factor 2, HGF, House, IL-6, Hepatocyte Stimulating Factor, Interferon beta-2, Mus musculus domesticus, Hybridoma growth factor, Growth Factor, Analysis, CTL differentiation factor, Mice, Drug Therapies, Differentiation Factor, Genomes, Analyses, Determination, Swiss, Hybridoma Growth Factor, Interleukin 6, Swiss Mice, B Cell., Sequence Determinations, Sequencing, B Cell Differentiation Factor 2, interleukin-6 receptor ligand, RNA Sequence Analyses, Therapies, RNA Sequencing, IL6, Sequence Analyses, Therapy, RNA, wide/broad, MGI-2, RNA Sequence Determinations, CASP14, mouse, B Cell Stimulatory Factor-2, beta-2, Myeloid Differentiation Inducing Protein, HSF, Cell, Determinations, BSF2, Interferon beta 2, Mus, IFN-beta-2, Mini-ICE, Chemotherapy, BSF-2, Differentiation Factor-2, B-Cell Differentiation Factor-2, Mus musculus, IFN-beta 2, Differentiation Factor 2, Pharmacotherapy, Caspase-14 subunit p10, distinct, mice, Swiss Mouse, Interleukin HP-1, House Mice, Caspase-14 subunit p19, whole genome, MICE, Plasmacytoma, Laboratory Mice, domesticus, Drug, wide, IFNB2, B Cell Differentiation Factor, Hybridoma, Plasmacytoma Growth Factor, RNA Sequence Analysis, B-Cell Stimulatory Factor 2, Mouse, pharmacologic therapy, Interferon, Laboratory MousefalseGenome-wide RNA sequencing on myeloid derived suppressor cells from mice treated with lymphodepleting chemotherapy reveals distinct IL-6 driven regulatory patternsGenome-wide RNA sequencing on myeloid derived suppressor cells from mice treated with lymphodepleting chemotherapy reveals distinct IL-6 driven regulatory patterns2025-09-242020-07-04PRJNA562907GSE13663910090